Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ORTX

Orchard Therapeutics (ORTX) Stock Price, News & Analysis

Orchard Therapeutics logo

About Orchard Therapeutics Stock (NASDAQ:ORTX)

Advanced Chart

Key Stats

Today's Range
$16.70
$16.70
50-Day Range
$16.40
$16.70
52-Week Range
$4.24
$16.72
Volume
N/A
Average Volume
157,287 shs
Market Capitalization
$380.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment.

Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.

Receive ORTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ORTX Stock News Headlines

The next market Nvidia is positioned to dominate …
Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang said, "The ChatGPT moment for robotics is right around the corner." In fact, I believe these robots could impact 65 million Americans lives — this year. And one stock — currently priced around $7 — could be the biggest winner.
See More Headlines

ORTX Stock Analysis - Frequently Asked Questions

Orchard Therapeutics plc (NASDAQ:ORTX) posted its quarterly earnings results on Monday, May, 15th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($1.61) by $1.49. The firm earned $1.24 million during the quarter, compared to the consensus estimate of $6.48 million. Orchard Therapeutics had a negative net margin of 333.90% and a negative trailing twelve-month return on equity of 74.94%.

Orchard Therapeutics shares reverse split on the morning of Friday, March 10th 2023. The 1-10 reverse split was announced on Friday, March 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Orchard Therapeutics (ORTX) raised $200 million in an initial public offering on Wednesday, October 31st 2018. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Orchard Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
5/15/2023
Today
4/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ORTX
Previous Symbol
NASDAQ:ORTX
Fax
N/A
Employees
166
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-150,660,000.00
Net Margins
-333.90%
Pretax Margin
-334.54%

Debt

Sales & Book Value

Annual Sales
$22.66 million
Price / Cash Flow
N/A
Book Value
$7.74 per share
Price / Book
2.16

Miscellaneous

Free Float
22,099,000
Market Cap
$380.09 million
Optionable
Optionable
Beta
0.55
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ORTX) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners